Image 01
Revlimid Capsule
Product Images NDC 59572-415
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Revlimid (NDC 59572-415). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Celgene Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image 02
This is medication information for Revlimid capsules with a strength of 5mg, indicated as prescription only. The National Drug Code for this product is 59572-405-28. The text contains a warning about the potential risks for human use. Some of the text is unreadable due to errors.*
Image 03
This is a medication called Revlimid in its 10mg capsule form. The packaging contains 28 capsules and has a National Drug Code (NDC) of 59572-410-28. It also includes a lot number of s20625, an expiration date of e77 and a street number of 1790C. The last few lines of text are not legible.*
Image 04
Revlimid (lenalidomide) is a prescription drug available in capsule form with a strength of 15mg. The NDC code for the drug is 50572-415-21. However, the rest of the text appears to be gibberish and cannot be understood.*
Image 05
Image 06
Chemical Structure (Revlimid 01)
Kaplan-meier Curves Of Progression-free Survival Based On Irac Assessment (itt Population) (Revlimid 02)
Kaplan-meier Curves Of Overall Survival (itt Population) (Revlimid 03)
Kaplan-meier Curves Of Progression-free Survival From Randomization (itt Post-asct Population) In Maintenance Study 1 (Revlimid 04)
This appears to be the results of a medical study, comparing the efficacy of Lenalidomide and a placebo for progression-free survival. The study found that Lenalidomide had a lower hazard ratio for progression-free survival and a higher median duration of progression-free survival compared to the placebo group. It also includes a graph showing the progression-free survival over time for both groups and the number of subjects at risk.*
Kaplan-meier Curves Of Progression-free Survival From Randomization (itt Post-asct Population) In Maintenance Study 2 (Revlimid 05)
This is a medical report including findings of the clinical trial of Lenalidomide for Progression-free Survival (PFS) in patients with a medical condition not mentioned in the report. The text includes numerical values of median response rate and percentage for the treatment group and placebo group and the number of subjects at risk.*
Kaplan-meier Estimate Of Time To Progression (Study 1)
The text appears to be a graph or chart showing the proportion of subjects over time in months, with a decrease in the number of subjects and a corresponding decrease in the hazard ratio (HR). The log rank p-value is less than 0.001. However, without more context or information, it is difficult to provide a more specific description.*
Kaplan-meier Estimate Of Time To Progression (Study 2)
This text appears to be a statistical analysis related to medical research, probably a clinical trial. It includes the proportion of subjects, HR value with confidence intervals, p-value, and the name of treatments (RevimidiDex and PlaceborDex) with some data related to them, such as sample size and time to progression in months.*
Revlimid 07a
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
